News

According to the company, this all-oral treatment is interferon (IFN) and ribavirin (RBV)-free and will be dosed once daily. In February 2015, the company submitted a new drug

Tremelimumab is one of a number of immuno-oncology products being developed by AstraZeneca and MedImmune to harness the body’s own immune system to fight cancer. The drug stimulates

In 2010, NewLink Genetics licensed Ebola vaccine candidate from its original developer the Public Health Agency of Canada’s National Microbiology Laboratory. Merck and NewLink have entered into an

Elocta is a long-acting recombinant factor VIII Fc fusion protein product candidate designed for patients with haemophilia A. Haemophilia is an inherited condition that regulates the blood’s ability

In this new oncology venture, VIB will become a shareholder alongside ThromboGenics, which will be the majority shareholder. ThromboGenics CEO Dr Patrik De Haes said: "The formation of

The deal will improve Hi-Tech’s Dietary Supplements and OTC product offering as well as expand its distribution through APN’s established platform. The transaction accelerates international growth strategy as

The Vancomycin 10g package is an addition to the company’s Vancomycin 5g pharmacy bulk package offering. The product is indicated to treat serious or severe infections caused by

The agency has issued the Prescription Drug User Fee Act (PDUFA) goal date in December 2015 for a decision on this NDA. The NDA seeks FDA approval of

Copanlisib is an intravenous pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor with predominant inhibitory activity against both PI3K-d and PI3K-a isoforms. The program now includes two new Phase III trials